

## List of figures

### Review of the literatures

**Figure I:** The common Opportunistic fungal infections.

**Figure II:** Examples of fungal infections.

**Figure III:** Risk factors predisposing to development of fungal infections.

**Figure IV:** Taxonomic classification of *Candida* and its phylogenetic relationship to other yeast species.

**Figure V:** Different clinical pictures of oropharyngeal candidiasis in HIV/AIDS patients.

**Figure VI:** Hypothetical defect in host cell defense against oropharyngeal candidiasis in HIV infection.

**Figure VII:** Risk factors in pathogenesis of Vulvovaginal candidiasis.

**Figure VIII:** Structures of antifungals used in Candidiasis treatment

**Figure IX:** Site and mechanism of action of different classes of antifungals on a typical fungal cell.

**Figure X:** Mechanism by which a *Candida albicans* cell might develop resistance.

**Figure XI:** Factors that may contribute to clinical resistance.

**Figure XII:** Schematic representation of depletion and enhancement theories of interactions between polyenes and azoles.

**Figure XIII:** The DENDRON system.

**Figure XIV:** The glyoxylate cycle and its interrelationship with other pathways.

**Figure XV:** Differential of *Candida* species by isolation on CHROMagar Candida.

## Materials and Methods

**Figure XVI:** Antifungal susceptibility testing of the yeast. Scheme shows the procedure for the MIC test following the NCCLS protocols.

**Figure XVII:** The principle of the Coulter Manual CD4<sup>+</sup> T-cells count kit used in this study.

**Figure XVIII:** Preparation of CARE-2 fragment.

**Figure XIX:** Image-processing and analysis.

## Results

**Figure 1:** Microscopic morphology of *Candida* species.

**Figure 2:** Microscopic morphology of the Gram's stain of clinical isolates.

**Figure 3:** *C. albicans*, germ tubes test.

**Figure 4:** The growth morphology of different *Candida* species on Tween corn meal agar.

**Figure 5:** Triphenyl tetrazolium chloride (TTC) reduction test.

**Figure 6:** Positive halo effect around an inoculated site on Tween opacity test.

**Figure 7:** Assimilation test of *Candida* species.

**Figure 8:** Percentage of oropharyngeal candidiasis (OPC) in HIV/AIDS patients.

**Figure 9:** Percentage of various *Candida* species isolated from HIV/AIDS patients with Oropharyngeal candidiasis.

**Figure 10:** colony morphology of *C. albicans* strains isolated from HIV/AIDS patients with oropharyngeal candidiasis.

**Figure 11:** The in vitro fluconazole susceptibility test of all the *Candida* isolates from HIV/AIDS with oropharyngeal candidiasis.

**Figure 12:** Relationship between the CD4+ -T-cells count and the appearance of the severity of OPC lesions in the HIV/AIDS patients.

**Figure 13:** DNA fingerprinting patterns of all *Candida* strains obtained from HIV/AIDS patients with oropharyngeal candidiasis.

**Figure 14:** Dendrogram of the *C. albicans* isolates (total No. 65) from HIV/ AIDS patients with OPC.

**Figure 15:** Percentage of vulvovaginal candidiasis (VVC) in Diabetic women.

**Figure 16:** Percentage of the *Candida* species isolated from Diabetic patients with vulvovaginal candidiasis.

**Figure 17:** Percentage of the *Candida* species isolated from non-diabetic patients with vulvovaginal candidiasis.

**Figure 18:** colony morphology of the *C. albicans* strains was isolated from diabetic women vulvovaginal candidiasis.

**Figure 19:** colonies morphology of the *C. glabrata* strains was isolated from diabetic women with vulvovaginal candidiasis.

**Figure 20:** The in vitro fluconazole susceptibility test of all the *Candida* isolates from diabetic and non-diabetic patients with vulvovaginal candidiasis

**Figure 21:** DNA fingerprinting pattern of the 21 *C. albicans* isolates, obtained from Diabetic patients with vulvovaginal candidiasis, (vaginal swabs).

**Figure 22:** Dendrogram of the *C. albicans* isolates (total No. 21) from diabetic patients with vulvovaginal candidiasis.

**Figure 23:** DNA fingerprinting pattern of the eight *C.albicans* isolates, obtained from non-diabetic patients with vulvovaginal candidiasis.

**Figure 24:** Dendrogram of the *C. albicans* isolates (total No. 8) obtained from non-diabetic patients with vulvovaginal candidiasis.

**Figure 25:** Agarose gel patterns demonstrating the AP-PCR with AP50-1 primer.

**Figure 26:** Agarose gel patterns demonstrating the AP-PCR with AP50-1 primer of the *C. glabrata* isolates obtained from diabetic patients with vulvovaginal candidiasis.

**Figure 27:** Agarose gel patterns demonstrating the AP-PCR with AP50-1 primer of the *C. glabrata* isolates obtained from non-diabetic patients with vulvovaginal candidiasis.

**Figure 28:** Spot test of resistant isolates.

**Figure 29:** Colonies morphology of the azole resistant strains of *C. albicans*.

**Figure 30:** Isocitrate lyase (ICL) activity (mU/mg protein) in the different clinical isolates of *C. albicans*.

**Figure 31:** Malate synthase (M S) activity (mU/mg protein) in the different clinical isolates of *C. albicans*.

**Figure 32:** Malate dehydrogenase (MDH) activity in the different clinical isolates of *C. albicans*.

**Figure 33:** Citrate synthase (CS) activity in the different clinical isolates of *C. albicans*.

**Figure 34:** RAPD pattern for *Candida* species obtained with primer ALI-8.

**Figure 35:** RAPD pattern of *C. albicans* obtained with primer ALI-8.

**Figure 36:** RAPD pattern of *C. dubliniensis* obtained with primer ALI-8.

**Figure 37:** RAPD pattern of *C. dubliniensis* obtained with primer ALI-8.

**Figure 38:** RAPD pattern of *C. tropicalis* obtained with primer ALI-8.

**Figure 39:** RAPD pattern of *C. glabrata* obtained with primer ALI-8.

**Figure 40:** RAPD pattern of *C. parapsilosis* obtained with primer ALI-8.

**Figure 41:** RAPD pattern of *C. krusei* obtained with primer ALI-8.

**Figure 42:** RAPD pattern of *C. pelliculosa* obtained with primer ALI-8.

**Figure 43:** Direct Colony RAPD pattern of *C. tropicalis* ATCC 750.